Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Casma Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 01, 2020
Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platform to discover novel small-molecule drug leads against a broad range of undisclosed Casma discovery targets.